LFCR
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Valuation is distorted by negative equity and lack of positive earnings.
- Low Price/Sales ratio (1.38)
- Negative Price/Book ratio
- Negative Forward P/E
- No Graham Number available
Growth is present but not yet translating into sustainable bottom-line profitability.
- Q/Q Revenue growth of 25.92%
- YoY EPS growth improvement
- Unreliable earnings track record
- Negative profit margins
Long-term performance is poor with high volatility in quarterly results.
- 3Y change is positive (+24.4%)
- 5Y change is deeply negative (-52.8%)
- Frequent and large earnings misses
Liquidity is currently sufficient, but solvency is a major concern due to debt levels.
- Strong Quick Ratio (2.18)
- Piotroski F-Score of 4/9 (Stable)
- Debt/Equity ratio of 4.15 is alarmingly high
- Negative equity
Company is in a growth/recovery phase and does not return capital to shareholders.
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LFCR and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LFCR
Lifecore Biomedical, Inc.
Primary
|
-52.8% | +24.4% | -17.0% | -26.9% | -30.2% | +23.7% |
|
KPTI
Karyopharm Therapeutics Inc.
Peer
|
-94.7% | -87.2% | +100.5% | +45.5% | -8.6% | +35.8% |
|
KRRO
Korro Bio, Inc.
Peer
|
-97.3% | -46.2% | -2.2% | -70.5% | +7.8% | -9.4% |
|
INGN
Inogen, Inc.
Peer
|
-88.6% | -52.4% | -10.6% | -22.4% | +1.6% | +1.9% |
|
LFMD
LifeMD, Inc.
Peer
|
-74.2% | +107.8% | -30.3% | -43.8% | -14.5% | -1.1% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q3 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LFCR
Lifecore Biomedical, Inc.
|
BEARISH | $178.02M | - | -% | -23.8% | $4.75 | |
|
KPTI
Karyopharm Therapeutics Inc.
|
BEARISH | $180.35M | - | -% | -134.2% | $8.0 | Compare |
|
KRRO
Korro Bio, Inc.
|
BEARISH | $182.88M | - | -110.7% | -% | $12.68 | Compare |
|
INGN
Inogen, Inc.
|
BEARISH | $172.38M | - | -12.4% | -6.5% | $6.33 | Compare |
|
LFMD
LifeMD, Inc.
|
BEARISH | $166.47M | - | -131.2% | 7.4% | $3.47 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | SALUS THOMAS D | Officer | Stock Award | 30,000 | - |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning LFCR from our newsroom.